Toleranzia AB publishes annual report for the financial year 2022
6 April - 2023
Toleranzia AB today publishes its annual report and auditors' report for the financial year 2022. The reports are available on the company's (www.toleranzia.se) and Nasdaq First North Growth Markets' (www.nasdaqomxnordic.com) websites.
For further information, please contact:
Charlotte Fribert – CEO, Toleranzia
Tel: +46 763 19 98 98
About Toleranzia AB (publ)
Toleranzia AB (publ) develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on the Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 01550, CA@mangold.se, is the company's Certified Adviser.